EGFR and non-small cell lung carcinoma: A striking example of the benefits of a predictive biomarker is the identification of the subset of patients with non-small cell lung cancer (NSCLC) patients who will respond to Epidermal Growth Factor Receptor (EGFR)-directed therapy.